ENGROSSEDS-0875.1 SUBSTITUTE SENATE BILL 5441 State of Washington 67th Legislature 2021 Regular Session By Senate Health & Long Term Care (originally sponsored by Senators Wellman, Cleveland, Das, and Lovelett)Lovelett READRead FIRSTfirst TIMEtime 02/15/21.02/09/21.

Referred to Committee on Health & Long Term Care.

1 ESSBSB 5441 (1) Beginning January 1, 2022, during the first consultation before breast implant surgery is performed, a physician licensed under chapter 18.71 RCW or an osteopathic physician licensed under chapter 18.57 RCW performs breast implant surgery, they must provide the patient with the following information in writing or in an electronic format:

(d) Information on anybreast surgicalimplant-associated meshanaplastic usedlarge duringcell breastlymphoma, implantincluding surgerynotice including,that butbreast notimplant-associated limitedanaplastic to,large meshcell madelymphoma ofoccurs nondegradablemore syntheticcommonly materials,in biodegradablepatients syntheticwith materials,textured orbreast animalimplants orthan humansmooth derivedimplants, tissues.and deaths have occurred;

This(e) informationInformation muston include a warning that no surgical mesh has been approved by the food and drug administration for use with breast implants;implant illness;

(e)(f) Information on breastthe implant-associatedsystemic anaplasticsymptoms largeassociation cell lymphoma, including notice that breast implant-associated anaplastic large cell lymphoma occurs more commonly in patients with textured breast implantsimplants; than smooth implants, and deaths have occurred;

(f)(g) Information on the national breast implant illness;registry;

(g)and (h) Information on thehow systemica symptomspatient associationcan report adverse events associated with breast implants;implants through the United States food and drug administration's medwatch program or any similar program.

(h) Information on the national breast implant registry;

and (i) Information on how a patient can report adverse events associated with breast implants through the United States food and drug administration's medwatch program or any similar program.

p.(4) A violation of this section constitutes unprofessional conduct under this chapter.

2 ESSB 5441 (4) A violation of this section constitutes unprofessional conduct under this chapter.

32 ESSBSB 5441